New hormonal therapies and regimens in the postmenopause: Routes of administration and timing of initiation

Climacteric

Volumn 10, Issue 5, 2007, Pages 358-370

  Sitruk Ware, R ^a,b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b POPULATION COUNCIL   (United States)

Author keywords

Estradiol; Hormonal therapy; Postmenopause; Progesterone; Progestins; Routes of administration; Sustained release systems; Timing of initiation

Indexed keywords

CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DRUG CARRIER; ELCOMETRINE; ESTRADIOL; ESTROGEN; ESTRONE; EVAMIST; GESTAGEN; LEVONORGESTREL; LIVER PROTEIN; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ACETATE; PROGESTERONE; STEROID; UNCLASSIFIED DRUG;

AEROSOL; BREAST CANCER; CANCER RISK; CARDIOVASCULAR RISK; CLINICAL TRIAL; COGNITION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; ENDOMETRIUM HYPERPLASIA; GEL; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; LOW DRUG DOSE; MENOPAUSAL SYNDROME; METERED DOSE INHALER; MONOTHERAPY; NONHUMAN; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RISK REDUCTION; SINGLE DRUG DOSE; SUBSTITUTION THERAPY; UTERUS; VAGINA RING;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; CONTROLLED CLINICAL TRIALS AS TOPIC; CORONARY DISEASE; DRUG ADMINISTRATION ROUTES; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; EVIDENCE-BASED MEDICINE; FEMALE; GELS; HUMANS; INTRAUTERINE DEVICES, MEDICATED; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; PROGESTERONE; PROGESTINS; UNITED STATES; WOMEN'S HEALTH;

EID: 34548627636     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130701609121     Document Type: Review

References (63)

1. Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women's Health Initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33
2. The WHI Steering Committee. Effect of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12
3. Beral V. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27
4. Phillips LS, Langer RD. Postmenopausal hormone therapy: critical reappraisal and a unified hypothesis. Fertil Steril 2005;83:558-66
5. Clark JH. A critique of Women's Health Initiative Studies (2002-2006). Nucl Recept Signal 2006;4:e-23
6. Pines A, Sturdee DW, Birkhäuser MH, et al., on behalf of the Board of the International Menopause Society. IMS Updated Recommendations on postmenopausal hormone therapy. Climacteric 2007;10:181-94
7. De Lignieres B, Basdevant A, Thomas G, et al. Biological effects of estradiol-17 beta in postmenopausal women: oral versus percutaneous administration. J Clin Endocrinol Metab 1986;62:536-41
8. Scarabin P-Y, Oger E, Plu-Bureau G, et al. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428-32
9. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007;115:840-5
10. Fournier A, Berrino F, Riboli E, et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2005;114:448-54
11. Fournier A, Berrino F, Clave-Chapelon F. Un-equal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2007 Feb 27; [Epub ahead of print].
12. Cicinelli E, de Ziegler D. Transvaginal progesterone: evidence for a new functional 'portal system' flowing from the vagina to the uterus. Hum Reprod Update 1999;5:365-72
13. Cicinelli E, de Ziegler D, Bulletti C, et al. Direct transport of progesterone from vagina to uterus. Obstet Gynecol 2000;95:403-6
14. Sitruk-Ware R. Delivery options for contraceptives. Drug Discov Today 2005;10:977-85
15. Sitruk-Ware R. Hormonal replacement therapy. A review. Rev Endocrine Metab Disorders 2002;3:243-56
16. Kuhl H. Pharmacology of estrogen and progestogens: influence of different routes of administration. Climacteric 2005;8(Suppl 1):3-63
17. Samsioe G. Transdermal hormone therapy: gels and patches. Climacteric 2004;7:347-56
18. Mishell DR Jr, Moore DE, Roy S, et al. Clinical performance and endocrine profiles with contraceptive vaginal rings containing a combination of estradiol and d-norgestrel. Am J Obstet Gynecol 1978;130:55-62
19. Nash HA, Sanchez-Alvarez F, Mishell DR Jr, et al. Estradiol-delivering vaginal rings for hormone replacement therapy. Am J Obstet Gynecol 1999;181:1400-6
20. Rigg LA, Hermann H, Yen SSC. Absorption of estrogens from vaginal creams. N Engl J Med 1978;298:195-7
21. Sitruk-Ware R, De Lignieres B, Basdevant A, et al. Absorption of percutaneous oestradiol in postmenopausal women. Maturitas 1980;2:207-11
22. Hossain M, Quebe-Fehling E, Sergejew T, et al. Comparative bioequivalence studies with Estradot and Menorest transdermal systems. Maturitas 2003;46:187-98
23. Humberstone AJ, Evans AM, Davis SR. A comparative study of the pharmacokinetics of testosterone (T) following administration of a Metered-Dose Transdermal Spray (MDTS) to the abdomen or forearm in healthy postmenopausal women with low serum testosterone. Presented at The Endocrine Society's 85th Annual Meeting; 2003, Philadelphia, USA, 2003, Abstr.
24. Studd J, Pornel B, Marton I, et al. for the Aerodiol Study Group. Efficacy and acceptability of intranasal 17β-oestradiol for menopausal symptoms: randomized dose-response study. Lancet 1999;353:1574-8
25. Sitruk-Ware R. New progestogens: a review of their effects in perimenopausal and postmenopausal women. Drugs Aging 2004;21:865-83
26. Shulman LP, Yankov V, Uhl K. Safety and efficacy of a continuous once-a-week 17beta-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized, controlled trials. Menopause 2002;3:195-7
27. The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1996;275:370-5
28. Miyagawa K, Rösch J, Stanczyk F, et al. Medroxyprogesterone acetate interferes with ovarian steroid protection against coronary vasospasm. Nature Med 1997;3:324-7
29. Rosano GM, Webb CM, Chierchia S, et al. Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. J Am Coll Cardiol 2000;36:2154-9
30. Sitruk-Ware R, Small M, Kumar N, et al. Nestorone®: clinical applications for contraception and HRT. Steroids 2003;68:907-13
31. Kumar N, Koide S, Tsong Y-Y, Sundaram K. Nestorone: a progestin with a unique pharmacological profile. Steroids 2000;65:629-36
32. de Ziegler D, Fanchin R. Progesterone and progestins: applications in gynecology. Steroids 2000;65:671-9
33. de Ziegler D, Ferriani R, Moraes LA, Bulletti C. Vaginal progesterone in menopause: Crinone 4% in cyclical and constant combined regimes. Hum Reprod 2000;15(Suppl 1):149-58
34. Cicinelli E, de Ziegler D, Alfonso R, Nicoletti R, Bellavia M, Colafiglio G. Endometrial effects, bleeding control, and compliance with a new postmenopausal hormone therapy regimen based on transdermal estradiol gel and every-other-day vaginal progesterone in capsules: a 3-year pilot study. Fertil Steril 2005;83:1859-63
35. Casanas-Roux F, Nisolle M, Marbaix E, et al. Morphometric, immunohistological and three-dimensional evaluation of the endometrium of menopausal women treated by oestrogen and Crinone, a new slow-release vaginal progesterone. Hum Reprod 1996;11:357-63
36. Zegers-Hochschild F, Balmaceda JP, Fabres C, et al. Prospective randomized trial to evaluate the efficacy of a vaginal ring releasing progesterone for IVF and oocyte donation. Hum Reprod 2000;15:2093-7
37. Alexander NJ, Baker E, Kaptein M, et al. Why consider vaginal drug administration? Fertil Steril 2004;82:12
38. Novak A, de la Loge C, Abetz L, et al. The combined contraceptive vaginal ring, NuvaRing: an international study of user acceptability. Contraception 2003;67:187-94
39. Carranza-Lira S, Gooch AL, Velasco-Díaz G, Solano J, Arzola-Paniagua A. Low and ultra low-dose estrogen therapy for climacteric symptom control - preliminary report. Int J Fertil Womens Med 2006;51:171-5
40. Sitruk-Ware R, Kumar N. Progestins and the brain. Effects on sexuality and quality of life. http://www.6thimsworkshop.com/sito/inside_pages/ proceedings/sitruk_ware.pdf
41. Mallareddy M, Hanes V, White WB. Drospirenone, a new progestogen, for postmenopusal women with hypertension. Drugs Aging 2007;24:453-66
42. Miles RA, Paulson RJ, Lobo RA, et al. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil Steril 1994;62:485-90
43. Maruo T, Mishell DR, Ben-Chetrit A, et al. Vaginal rings delivering progesterone and estradiol may be a new method of hormone replacement therapy. Fertil Steril 2002;78:1010-16
44. Croxatto HB, Zepeda A. Transdermal contraceptive systems: innovative technology for the twenty-first century. In Sitruk-Ware R, Bardin W, eds. Contraception. Newer Pharmacological Agents, Devices, and Delivery Systems. New York: Marcel Dekker, Inc, 1992:101-15
45. Rubinacci A, Peruzzi E, Modena AB, et al. Effect of low-dose transdermal E2/NETA on the reduction of postmenopausal bone loss in women. Menopause 2003;10:241-9
46. Sturdee DW, van de WP, von Holst T. Endometrial safety of a transdermal sequential estradiol-levonorgestrel combination. Climacteric 2002;5:170-7
47. Luukkainen T, Lahteenmaki P, Toivonen J. Levonorgestrel-releasing intrauterine device. Ann Med 1990;22:85-90
48. Sitruk-Ware R, Inki P. The levonorgestrel intrauterine system: long-term contraception and therapeutic effects. Women's Health 2005;1:171-82
49. Sturdee DW, Rantala ML, Colau JC, et al. The acceptability of a small intrauterine progestogen-releasing system for continuous combined hormone therapy in early postmenopausal women. Climacteric 2004;7:404-11
50. Burger HG, Dudley EC, Robertson DM, Dennerstein L. Hormonal changes in the menopause transition. Recent Prog Horm Res 2002;57:257-75
51. Critchley H. Endometrial effects of progestogens. Gynecol Forum 2003;8:6-10
52. Jones RL, Critchley HO. Morphological and functional changes in human endometrium following intrauterine levonorgestrel delivery. Hum Reprod 2000;15(Suppl 3):S162-72
53. Backman T, Rauramo I, Jaakkola K, et al. Use of the levonorgestrel-releasing intrauterine system and breast cancer. Obstet Gynecol 2005;106:813-7
54. Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas 2006 20;55(2):103-15. Epub 2006 Jul 11
55. Wood CE, Sitruk-Ware R, Tsong YY, et al. Effects of estradiol with oral or intravaginal progesterone on risk markers for breast cancer in a postmenopausal monkey model. Menopause 2007;14:1-9
56. Wood CE, Register TC, Lees CJ, Chen H, Kimrey S, Cline JM. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys. Breast Cancer Res Treat 2007;101:125-34
57. Montplaisir J, Lorrain J, Denesle R, et al. Sleep in menopause: differential effects of two forms of hormone replacement therapy. Menopause 2002;8:10-16
58. Kuhl H. Effects of progestogens on haemostasis. Maturitas 1996;24:1-19
59. Pinkerton J, Santen R. Alternatives to the use of estrogen in postmenopausal women. Endocrine Rev 1999;20:308-20
60. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Women's Health (Larchmt) 2006;15:35-44
61. Shumaker SA, Legault C, Rapp SR, et al. WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2651-62
62. Nilsen J, Brinton RD. Impact of progestins on estrogen-induced neuroprotection: synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate. Endocrinology 2002;143:205-12
63. Sitruk-Ware R, Plu-Bureau G. Exogenous progestagens and the human breast. Maturitas 2004;49:58-66